Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $658.6KOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Vitoc Vlad | Chief Executive Officer | Jun 01 '26 | Buy | $1.39 | 72,700 | $100,886 | 976,121 | Jun 02 09:02 AM |
| Smith Stan | Director | Jun 01 '26 | Buy | $1.34 | 75,000 | $100,200 | 1,519,178 | Jun 02 09:01 AM |
| Gryaznov Sergei | Chief Scientific Officer | Jun 01 '26 | Buy | $1.34 | 2,000 | $2,690 | 46,511 | Jun 02 09:00 AM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.